AURO-MODAFINIL 100 MG
MODAFINIL : 100 MG · DIN 02430487 · AURO PHARMA INC
Health Canada status: MARKETED
What is AURO-MODAFINIL?
AURO-MODAFINIL 100 MG contains MODAFINIL : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02430487, held by AURO PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Oct-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AURO-MODAFINIL used for?
Auro-Modafinil (modafinil) is indicated for: The symptomatic treatment of excessive sleepiness in adult patients with narcolepsy. In narcolepsy, modafinil has no significant effect on cataplexy. The symptomatic treatment of excessive sleepiness in adult patients with obstructive sleep apnea (OSA). In OSA, Auro-Modafinil is indicated as an adjunct to successful standard treatment(s) for the underlying obstruction, when excessive sleepiness persists. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient with OSA, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating Auro-Modafinil. If Auro-Modafinil is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. The symptomatic treatment of excessive sleepiness in adult patients with circadian rhythm sleep disorder, shift work type (shift work disorder) (SWD). In SWD, Auro-Modafinil (modafinil) is indicated for the symptomatic treatment of excessive sleepiness (as confirmed by multiple sleep latency test) associated with loss of a normal sleep-wake pattern (as confirmed by polysomnography).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02430487 |
|---|---|
| Brand name | AURO-MODAFINIL |
| Generic / active ingredient | MODAFINIL : 100 MG |
| Manufacturer | AURO PHARMA INC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06BA07 MODAFINIL |
| AHFS class | 28:20.80 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Oct-2014 |
| Original market date | 2014-10-24 00:00:00 |
How is it stored and handled?
null
How is it supplied?
Available in blister packs of 3 x 10’s count; Available in bottles of 100 tablets
What can be used instead?
Other Canadian products sharing ATC code N06BA07 MODAFINIL. 7 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALERTEC | 100 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02239665 |
| APO-MODAFINIL | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02285398 |
| JAMP MODAFINIL | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02503727 |
| MAR-MODAFINIL | 100 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02432560 |
| MODAFINIL | 100 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02530244 |
| TEVA-MODAFINIL | 100 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02420260 |
| BIO-MODAFINIL | 100 MG | TABLET | BIOMED PHARMA | CANCELLED POST MARKET | DIN 02442078 |
| IPG-MODAFINIL | 100 MG | TABLET | MARCAN PHARMACEUTICALS INC | APPROVED | DIN 02432013 |
| MODAFINIL TABLETS | 100 MG | TABLET | STRIDES PHARMA CANADA INC | APPROVED | DIN 02479303 |
Who else supplies MODAFINIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MODAFINIL appears in 69 registered pack listings across 10 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.